NovoCure Ltd. (NASDAQ: NVCR), a global oncology company, saw its stock plummet 5.3% in the intraday trading session on Friday, following the release of its full-year 2024 earnings results.
The company reported revenue of $605.2 million for the fiscal year 2024, up 19% year-over-year and in line with analyst estimates. However, NovoCure's earnings per share (EPS) fell short of expectations, missing by 20% at a loss of $1.56 per share.
The EPS miss appears to have weighed heavily on investor sentiment, as the company's shares had already experienced an 11% decline over the past week leading up to the earnings release. While NovoCure's revenue growth remained solid, the wider-than-expected net loss suggests potential challenges in managing costs or meeting profitability targets.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。